Citius Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on June 23, 2016. The filing reports corporate governance changes, specifically the appointment of a new director and amendments to the company's bylaws.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation and stock option grants:
- Director Retainer: $10,000 annually for Board service.
- Committee Fees: $5,000 annually for service on the Compensation and Nominating and Governance Committees.
- Meeting Fees: $2,000 for in-person meetings and $500 for teleconference meetings.
- Stock Options: 200,000 shares granted to each of four directors (Mr. Safir, Ms. Webb, Dr. Kane, and Dr. Holuka) with an exercise price of $0.80 per share.
Material Changes
The following material changes were approved by the Board on June 23, 2016:
- Board Expansion: The Board size increased from six to seven members.
- New Appointment: Eugene Myron Holuka was appointed to the Board and as a member of the Compensation Committee and Nominating and Governance Committee.
- Bylaw Amendment: Article III, Section 3.2 of the Amended and Restated Bylaws was amended to allow the Board to set the number of directors at any time, provided the Board consists of at least six directors.
Outlook, Risks, and Unusual Items
The filing contains no management commentary regarding business outlook, risks, or contingencies. The stock options granted to directors vest in full on June 23, 2017. The filing explicitly states there are no related person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 800,000 new options granted (200,000 to each of four directors).
- Confirm the current market price of the stock relative to the $0.80 exercise price of the newly granted options.
- Review the full text of the Amended and Restated Bylaws (Exhibit 3.2) to understand the full scope of the Board's new authority to adjust its size.
- Check subsequent filings for the formal election of Dr. Holuka at the next annual meeting of shareholders.